Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.

@article{Tronvik2003ProphylacticTO,
  title={Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.},
  author={Erling Tronvik and Lars Stovner and Grethe Helde and Trond Sand and Gunnar Bovim},
  journal={JAMA},
  year={2003},
  volume={289 1},
  pages={
          65-9
        }
}
CONTEXT There is a paucity of effective, well-tolerated drugs available for migraine prophylaxis. OBJECTIVE To determine whether treatment with the angiotensin II receptor blocker candesartan is effective as a migraine-prophylactic drug. DESIGN AND SETTING Randomized, double-blind, placebo-controlled crossover study performed in a Norwegian neurological outpatient clinic from January 2001 to February 2002. PATIENTS Sixty patients aged 18 to 65 years with 2 to 6 migraine attacks per month… Expand

Paper Mentions

Observational Patient Registry Clinical Trial
Observational, prospective, descriptive, open study on response predictors and tolerability of Candesartan in patients >18 years with episodic or chronic migraine with prior failure of… Expand
ConditionsHead Pain, Migraine
InterventionDrug
Interventional Clinical Trial
The main aim of the present study is to compare candesartan with propranolol for migraine prophylaxis.  
ConditionsChronic Migraine, Migraine With Aura, Migraine Without Aura
InterventionDrug
Interventional Clinical Trial
The purpose of this study is to determine whether candesartan cilexetil are effective prophylactic treatment of episodic Cluster headache  
ConditionsCluster Headache
InterventionDrug
Lisinopril as a prophylactic agent for migraine: a randomised double blind placebo controlled cross over prospective study in Kashmir
TLDR
This study favours lisinopril as an effective prophylactic drug for migraine, though of significant frequency, have been mild to moderate in severity but were well tolerated by even normotensive subjects. Expand
Randomised trial on episodic cluster headache with an angiotensin II receptor blocker
TLDR
Post-hoc statistics suitable to describe the temporal changes in cluster headache indicate that conduction of future larger studies may be justified, and the difference between the candesartan and placebo group was not significant with the pre-planned non-parametric ranking test. Expand
Topiramate for migraine prevention: a randomized controlled trial.
TLDR
Topiramate showed significant efficacy in migraine prevention within the first month of treatment, an effect maintained for the duration of the double-blind phase. Expand
Telmisartan in Migraine Prophylaxis: A Randomized, Placebo-Controlled Trial
TLDR
It is indicated that telmisartan might be effective in migraine prophylaxis, and a borderline significant difference in responders is seen. Expand
Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial
TLDR
The results support the previous suggestions on usage of ACE inhibitors in migraine prophylaxis and Enalapril according to its effect in decreasing the frequency, severity, and duration of headaches. Expand
Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study
TLDR
C candesartan showed beneficial effects in the preventive treatment of migraine in clinical practice, including patients with chronic migraine, medication-overuse headache and resistance to prior prophylactics. Expand
The crossover design for migraine preventives: an analyses of four randomized placebo-controlled trials
TLDR
Summary data from four crossover trials evaluating preventive treatment in adult migraine showed that few dropped out after the first period, and no period or carryover effect was found. Expand
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study
TLDR
It is confirmed that candesartan 16 mg is effective for migraine prevention, with an effect size similar to propranolol 160 mg, and with somewhat different adverse events. Expand
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials
TLDR
Lasmiditan was more effective than placebo for the acute treatment of migraine in patients concurrently using migraine preventive medications and rates of adverse events were similar for patients using and not using preventive medications. Expand
Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study
TLDR
The results support the theory that auras are caused by CSD and that this phenomenon is not involved in attacks without aura, and Tonabersat was well tolerated but overall had more side-effects than placebo. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study
TLDR
Analysis of data from 55 patients supported the differences in favour of lisinopril for the primary end points, and concluded that the angiotensin converting enzyme inhibitor, lisinobril, has a clinically important prophylactic effect in migraine. Expand
Antiepileptic Drugs in Migraine Prevention
TLDR
Large, double‐blind, placebo‐controlled trials may prove the effectiveness of novel antiepileptic drugs in migraine prevention. Expand
Sodium Valproate in The Prophylactic Treatment of Migraine: A Double-Blind Study Versus Placebo
TLDR
The efficacy of sodium valproate (Depalept) versus placebo in the treatment of migraine was evaluated in a double-blind randomized cross-over study and the drug was well tolerated and proved to be an effective treatment in migraine. Expand
Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis.
TLDR
Angiotensin II receptor antagonists appear to be effective in preventing headaches, but the mechanism of this benefit and the types of headaches that are prevented are not known. Expand
The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers.
TLDR
Uncertainties regarding the relative merits of various treatment modalities are largely caused by lack of adherence to specific requirements for clinical trials on migraine prophylaxis. Expand
Efficacy and Tolerability in Migraine Prophylaxis of Flunarizine in Reduced Doses: A Comparison with Propranolol 160 Mg Daily
TLDR
The results of this equivalence trial show that 10 mg flunarizine daily with a drug-free weekend is at least as effective as 160 mg propranolol in the prophylaxis of migraine for all evaluated parameters (one-sided equivalence tests) after 16 weeks of treatment. Expand
A Quantification of the Placebo Response in Migraine Prophylaxis
TLDR
It is proposed that if the percentage of responders in an open-label prophylactic trial in migraine is above 35-40%, or if a reduction in migraine attack frequency is found of 40% or more, further studies are indicated to determine the prophyllactic activity of the drug. Expand
Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials
BACKGROUND The triptans, selective serotonin 5-HT(1B/1D) agonists, are very effective acute migraine drugs with a well- developed scientific rationale. Seven different triptans will soon beExpand
Effects of Candesartan on Cough and Bronchial Hyperresponsiveness in Mildly to Moderately Hypertensive Patients With Symptomatic Asthma
TLDR
There were no differences between the 2 groups in patient characteristics, ACE gene polymorphism, pulmonary function, or bronchial hyperresponsiveness to methacholine, and the adverse effects of candesartan and calcium antagonists on cough, lung function, and bronchia hyperresponsivity in these patients. Expand
Candesartan cilexetil: an angiotensin II-receptor blocker.
  • S. See, A. L. Stirling
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2000
TLDR
It appears that candesartan can decrease renal perfusion without adversely affecting renal blood flow and may mediate a decrease in albuminuria in hypertensive patients with type 2 diabetes. Expand
...
1
2
3
4
...